Skip to content
Inciteful Med

Standard of Care Treatment for Anterior Uveitis

Last updated:

The standard treatment for non-infectious anterior uveitis involves topical steroid eye drops to reduce inflammation and dilating drops to relieve pain and prevent permanent eye damage. Steroids must be shaken vigorously and tapered slowly to prevent rebound flare-ups.

Key Takeaways

  • • Topical corticosteroids like prednisolone acetate are the primary first-line treatment for non-infectious anterior uveitis.
  • • Prednisolone acetate drops must be shaken vigorously at least 20 times before every use so the active medication does not settle at the bottom.
  • • Dilating drops are prescribed alongside steroids to stop painful muscle spasms and prevent the iris from sticking to the lens.
  • • Steroid drops must be tapered slowly over 4 to 6 weeks rather than stopped suddenly to prevent inflammation from rebounding.
  • • Long-term use of steroid eye drops requires careful monitoring for side effects like elevated eye pressure and cataracts.

The primary goals of treating anterior uveitis are to quiet the inflammation, relieve your pain, and prevent long-term damage to your vision [1][2]. Treatment is typically divided into two main categories: non-infectious (immune-related) and infectious (germ-related) [1]. Even with proper and prompt treatment, an acute flare of anterior uveitis may take 4 to 8 weeks to fully resolve [3].

First-Line Treatment: Non-Infectious Uveitis

For most patients, the initial treatment involves two types of eye drops used together:

1. Topical Corticosteroids

These are powerful anti-inflammatory medications that “turn off” the immune response in your eye [4].

  • Common Medications: Prednisolone acetate 1% is the standard first choice [4]. Important Warning: Prednisolone acetate is a suspension. You must shake the bottle vigorously (at least 20 times) before every single use. If you do not shake it, the active medication settles at the bottom, and you will only put inactive liquid in your eye, leading to treatment failure and prolonged inflammation [4]. Your doctor might also prescribe difluprednate (Durezol), which is a stronger emulsion that usually requires fewer drops per day and does not need to be shaken as vigorously [5][6].
  • The Taper: You must never stop steroid drops suddenly. Once the inflammation is controlled, your doctor will provide a “tapering” schedule to slowly reduce the dose over 4 to 6 weeks. This prevents the inflammation from “rebounding” [7][8].

2. Dilating (Mydriatic/Cycloplegic) Drops

These drops, such as cyclopentolate or atropine, serve two critical purposes [2][7]:

  • Pain Relief: They temporarily paralyze the ciliary muscle inside the eye, which stops the painful spasms that cause deep aching and light sensitivity [2][8].
  • Preventing “Synechiae”: They keep the pupil dilated so the iris does not get “stuck” to the lens behind it, which can cause permanent pupil irregularity or glaucoma [2].

Immediate Side Effects Warning: Because these drops paralyze the focusing muscle and lock your pupil wide open, you will experience sudden, profound near-vision blurriness and extreme light sensitivity. This is completely normal and means the medication is working—it does not mean your disease is worsening [2]. You should wear dark sunglasses (even indoors if needed) and avoid driving until your vision clears.

Treating Infectious Uveitis

If an infection is the cause, steroids alone are not enough and could actually make the situation worse [9][10].

  • Viruses (Herpes/CMV): These require antiviral medications like acyclovir, valacyclovir, or valganciclovir, often used alongside a low dose of steroids to manage the resulting inflammation [1][11].
  • Bacterial (Syphilis/TB): These require specific systemic antibiotics, such as penicillin for syphilis or a multi-drug regimen (RIPE) for tuberculosis, which can last 6 to 9 months [12][13].

Moving to Second-Line Therapy

If your uveitis is chronic, recurs frequently, or does not respond to drops, your doctor may move to “steroid-sparing” treatments to avoid the side effects of long-term steroid use [14][15].

  • Immunomodulatory Agents (IMAs): Oral medications like methotrexate or mycophenolate mofetil that help regulate the immune system more broadly [16][17].
  • Biologics: Targeted injections like adalimumab (Humira) or infliximab (Remicade), which are often used for severe cases associated with autoimmune diseases [18][19].

Important Side Effects to Watch For

While steroids are effective, long-term use (more than a few weeks) carries risks:

  • Ocular Hypertension (IOP Spikes): About 28% to 46% of people are “steroid responders,” meaning the drops cause their eye pressure to rise, which can lead to glaucoma if not monitored [20][21].
  • Cataracts: Prolonged steroid use is a major cause of lens clouding (cataracts), which may eventually require surgery [4][22].

Regular follow-up appointments are essential to monitor these risks and ensure the treatment is working effectively [23][24].

Frequently Asked Questions

Why do I need to shake my prednisolone eye drops?
Prednisolone acetate is a suspension, meaning the active medication settles at the bottom. If you do not shake the bottle vigorously before every single use, you will only put inactive liquid in your eye, leading to treatment failure and continued inflammation.
Why is a tapering schedule important for steroid eye drops?
You must never stop steroid eye drops suddenly. Slowly reducing the dose over four to six weeks prevents the inflammation from rebounding and returning. Your eye doctor will provide a specific tapering schedule based on how your eye is healing.
What is the purpose of dilating drops for uveitis?
Dilating drops temporarily paralyze the eye's focusing muscle, which stops painful spasms and relieves deep aching. They also keep your pupil wide open so the iris does not stick to the lens behind it, preventing permanent pupil irregularity or glaucoma.
Is it normal to have blurry vision and light sensitivity from dilating drops?
Because dilating drops paralyze the focusing muscle and lock your pupil wide open, sudden near-vision blurriness and extreme light sensitivity are completely normal. This means the medication is working properly and does not mean your condition is worsening.
What are the risks of using steroid eye drops long-term?
Using steroid eye drops for more than a few weeks can cause your eye pressure to rise, which may lead to glaucoma if not closely monitored. Prolonged use is also a major cause of cataracts, which is a clouding of the eye's lens.

Questions for Your Doctor

  • • What is my specific tapering schedule for these steroid drops, and why is it important not to stop them suddenly?
  • • Is the dilating drop I’m using intended only for pain relief, or is it also helping to prevent my iris from sticking to the lens?
  • • Since I'm using steroids, how often will you be monitoring my eye pressure and checking for signs of cataracts?
  • • At what point would we consider switching from eye drops to a systemic medication or a 'steroid-sparing' agent?
  • • Given my history, should we be testing for an underlying infection like Herpes or CMV before continuing long-term steroids?

Questions for You

  • • Am I able to follow a strict schedule for multiple eye drops throughout the day?
  • • Is my eye pain improving after I use the dilating drops, or do I still feel a deep ache?
  • • Have I noticed any side effects from the drops, such as a 'full' feeling in my eye or a change in how clear my vision is?
  • • How many times has this eye inflammation returned after I finished a course of treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective.

    Zandi S, Bodaghi B, Garweg JG

    Ocular immunology and inflammation 2018; (26(7)):1135-1142 doi:10.1080/09273948.2018.1498109.

    PMID: 30096015
  2. 2

    Topical mydriatics as adjunctive therapy for traumatic iridocyclitis.

    Hom J, Sarwar S, Kaleem MA, et al.

    The Cochrane database of systematic reviews 2020; (8()):CD013260 doi:10.1002/14651858.CD013260.pub2.

    PMID: 35659470
  3. 3

    [Uveitis in spondyloarthritis].

    Rudwaleit M, Walscheid K, Heiligenhaus A

    Zeitschrift fur Rheumatologie 2017; (76(8)):682-692 doi:10.1007/s00393-017-0357-6.

    PMID: 28812149
  4. 4

    [Topical Corticosteroids and Non-steroidal Anti-inflammatory Drugs in the Therapy of Non-infectious Uveitis].

    Doycheva D, Deuter C, Grajewski R

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(5)):586-591 doi:10.1055/a-0590-4546.

    PMID: 29739028
  5. 5

    Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies.

    Sheppard JD, Foster CS, Toyos MM, et al.

    Ocular immunology and inflammation 2019; (27(3)):484-496 doi:10.1080/09273948.2017.1407433.

    PMID: 29260952
  6. 6

    Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis.

    KhalafAllah MT, Basiony A, Salama A

    BMJ open 2019; (9(11)):e026752 doi:10.1136/bmjopen-2018-026752.

    PMID: 31678934
  7. 7

    A case of severe flare reaction observed in HLA B27 associated acute anterior uveitis.

    Kim JI, Park CY

    BMC ophthalmology 2020; (20(1)):201 doi:10.1186/s12886-020-01472-3.

    PMID: 32448152
  8. 8

    Bilateral Acute Anterior Uveitis and Conjunctivitis following Intravenous Zoledronic Acid.

    Chatterjee S, Agrawal D

    The Journal of the Association of Physicians of India 2017; (65(7)):110-111.

    PMID: 28792180
  9. 9

    Unusual pattern of herpetic optic neuropathy: a case report and literature review of the pathophysiology of herpetic uveitis.

    Helal RS, Abu Sbeit R, Al-Baker ZM

    Journal of ophthalmic inflammation and infection 2023; (13(1)):12 doi:10.1186/s12348-023-00335-4.

    PMID: 36943518
  10. 10

    Polymerase chain reaction in unilateral cases of presumed viral anterior uveitis.

    Shoughy SS, Alkatan HM, Al-Abdullah AA, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):2325-8 doi:10.2147/OPTH.S93655.

    PMID: 26715836
  11. 11

    Interventions for the management of CMV-associated anterior segment inflammation.

    Anshu A, Tan D, Chee SP, et al.

    The Cochrane database of systematic reviews 2017; (8()):CD011908 doi:10.1002/14651858.CD011908.pub2.

    PMID: 28838031
  12. 12

    Insights into ocular syphilis in Nepal.

    Sharma S, Kharel R, Parajuli S, et al.

    International journal of STD & AIDS 2024; (35(7)):527-534 doi:10.1177/09564624241232451.

    PMID: 38426703
  13. 13

    Presumed ocular tuberculosis in the United Kingdom: a British Ophthalmological Surveillance Unit (BOSU) study.

    Shirley K, Dowlut S, Silvestri J, et al.

    Eye (London, England) 2020; (34(10)):1835-1841 doi:10.1038/s41433-019-0748-9.

    PMID: 31896802
  14. 14

    Uveitis in Children and Adolescents.

    Chang MH, Shantha JG, Fondriest JJ, et al.

    Rheumatic diseases clinics of North America 2021; (47(4)):619-641 doi:10.1016/j.rdc.2021.07.005.

    PMID: 34635295
  15. 15

    Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients.

    Nguyen AT, Koné-Paut I, Dusser P

    Paediatric drugs 2024; (26(1)):31-47 doi:10.1007/s40272-023-00596-5.

    PMID: 37792254
  16. 16

    Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.

    Oray M, Tuğal-Tutkun İ

    Turkish journal of ophthalmology 2016; (46(2)):77-82 doi:10.4274/tjo.09581.

    PMID: 27800265
  17. 17

    The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis.

    Waszczyk-Łączak M, Łazicka-Gałecka M, Chomicz L, et al.

    Annals of agricultural and environmental medicine : AAEM 2020; (27(4)):644-649 doi:10.26444/aaem/125837.

    PMID: 33356073
  18. 18

    Therapeutic advances in juvenile idiopathic arthritis - associated uveitis.

    Gueudry J, Touhami S, Quartier P, Bodaghi B

    Current opinion in ophthalmology 2019; (30(3)):179-186 doi:10.1097/ICU.0000000000000559.

    PMID: 30844943
  19. 19

    A Case of Bullous Morphea Resistant to Methotrexate and Phototherapy Successfully Treated With Mycophenolate Mofetil.

    Cuellar-Barboza A, Alberto Cardenas-De La Garza J, Daniel Villarreal-Villarreal C, et al.

    Journal of drugs in dermatology : JDD 2018; (17(10)):1123-1125.

    PMID: 30365594
  20. 20

    Aetiology and clinical characteristics of uveitic glaucoma in Turkish patients.

    Altan C, Basarir B

    International ophthalmology 2021; (41(6)):2225-2234 doi:10.1007/s10792-021-01783-4.

    PMID: 33730317
  21. 21

    Characteristics of ocular hypertension and uveitic glaucoma among patients with noninfectious uveitis.

    Felfeli T, Rhee J, Eshtiaghi A, et al.

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024; (59(6)):430-438 doi:10.1016/j.jcjo.2024.02.003.

    PMID: 38431271
  22. 22

    Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

    Gaballa SA, Kompella UB, Elgarhy O, et al.

    Drug delivery and translational research 2021; (11(3)):866-893 doi:10.1007/s13346-020-00843-z.

    PMID: 32901367
  23. 23

    Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases.

    Yang YH, Kuo HH, Hsu WC, Hsieh YT

    International journal of ophthalmology 2020; (13(6)):946-951 doi:10.18240/ijo.2020.06.14.

    PMID: 32566507
  24. 24

    Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension.

    Yasuda M, Takayama K, Kanda T, et al.

    PloS one 2017; (12(10)):e0185305 doi:10.1371/journal.pone.0185305.

    PMID: 28968412

This page explains standard treatments for anterior uveitis for educational purposes only. Your ophthalmologist is the best source for your specific eye care, medication schedule, and disease monitoring.

Stay up to date

Get notified when new research about Anterior uveitis is published.

No spam. Unsubscribe anytime.